Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Cancer Immunol Immunother. 2019 Dec 5;69(1):95–102. doi: 10.1007/s00262-019-02442-5

Figure 1:

Figure 1:

Schema of illustrating the proposed trial design. Cohort, group, arm, and zone designation for the proposed study to test safety and immunogenicity of vaccination with the 12 class I major histocompatibility complex-restricted melanoma peptides (Mel12.1) with specified combinations of polyICLC (poly), incomplete Freund’s adjuvant (IFA), CD40 antibody, and with/without CD27 antibody (+/−).